<DOC>
	<DOCNO>NCT00968708</DOCNO>
	<brief_summary>The purpose study evaluate cardiovascular outcome alogliptin , daily ( QD ) , compare placebo , addition standard care , patient type 2 diabetes mellitus acute coronary syndrome .</brief_summary>
	<brief_title>Cardiovascular Outcomes Study Alogliptin Patients With Type 2 Diabetes Acute Coronary Syndrome</brief_title>
	<detailed_description>Alogliptin selective potent dipeptidyl peptidase-4 inhibitor develop Takeda use patient type 2 diabetes mellitus . Cardiovascular outcomes special interest type 2 diabetes mellitus population , particularly type 2 diabetes mellitus patient cardiovascular disease high risk major adverse cardiac event , patient recent acute coronary syndrome . This study design evaluate cardiovascular safety alogliptin versus placebo addition Standard Care adult type 2 diabetes mellitus acute coronary syndrome .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus Is receive monotherapy combination antidiabetic therapy glycosylated hemoglobin level 6.5 % 11.0 % , inclusive , Screening ( 7.0 11.0 % , inclusive , participant 's antidiabetic regimen include insulin ) Diagnosis acute coronary syndrome within 15 90 day prior randomization . Signs type 1 diabetes mellitus Currently receive glucagonlike peptide1 analogue glycemic control type 2 diabetes mellitus Screening Received dipeptidyl peptidase4 inhibitor either 14 day total within 3 month prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Diabetes Mellitus - Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>cardiovascular outcome</keyword>
	<keyword>heart attack</keyword>
	<keyword>stroke</keyword>
	<keyword>dipeptidyl-peptidase IV inhibitor</keyword>
	<keyword>metabolic disorder</keyword>
	<keyword>metabolic disease</keyword>
	<keyword>glucose metabolism disorder</keyword>
</DOC>